乳腺癌新辅助治疗策略的研究进展

新辅助治疗作为乳腺癌的重要治疗手段,其适应证已不仅限于局晚期乳腺癌.病理完全缓解(pathologic complete response,pCR)与新辅助治疗后患者总生存率(overall survival,OS)及无病生存率(disease-free survival,DFS)的提高显著相关,是新辅助治疗最为客观高...

Research progress of neoadjuvant therapy strategies for breast cancer

As an essential treatment for breast cancer,neoadjuvant therapy is not limited to locally advanced breast cancer.Pathologic complete response(pCR)is significantly related to the improvement of overall survival(OS)rate and disease-free survival(DFS)rate after neoadjuvant therapy.It is the most objective and efficient evaluation index of neoadjuvant therapy.After neoadjuvant therapy,patients can achieve important diagnosis and treatment purposes such as tumor downgrading,improving breast preservation rate,and sufficient observation of tumor drug sensitivity.Accurate efficacy analysis can help clinicians switch their diagnosis and treatment strategies in time,provide patients with individualized treatment plans,and avoid undertreatment or overtreatment.This article reviews the latest research progress on the problems of anthracycline removal in neoadjuvant chemotherapy,neoadjuvant targeted therapy for HER2-positive breast cancer,neoadjuvant immunotherapy for triple-negative breast cancer,the timing of surgery and choice of surgical methods.